Kura Oncology Logo
Kura Oncology to Report Second Quarter 2018 Financial Results
30. Juli 2018 16:05 ET | Kura Oncology, Inc.
SAN DIEGO, July 30, 2018 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today...
Kura Oncology Logo
Kura Oncology Announces Pricing of $67 Million Public Offering of Common Stock
28. Juni 2018 07:30 ET | Kura Oncology, Inc.
SAN DIEGO, June 28, 2018 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq:KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today...
Kura Oncology Logo
Kura Oncology Announces Commencement of Public Offering of Common Stock
27. Juni 2018 16:01 ET | Kura Oncology, Inc.
SAN DIEGO, June 27, 2018 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq:KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today...
Kura Oncology Logo
Kura Oncology Appoints Chief Operating Officer, Expands Clinical Development Team as Company Prepares for First Registration-Directed Trial
20. Juni 2018 07:30 ET | Kura Oncology, Inc.
– John Farnam appointed to newly created position of Chief Operating Officer – – Bridget Martell, M.D., and Blake Tomkinson, Ph.D., join as Vice Presidents of Clinical Development – –...
Kura Oncology Logo
Kura Oncology Announces Upcoming Presentations at AACR Annual Meeting 2018
09. April 2018 07:30 ET | Kura Oncology, Inc.
SAN DIEGO, April 09, 2018 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq:KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today...
Kura Oncology Logo
Kura Oncology Doses First Patient in Phase 2 Study of Tipifarnib in Chronic Myelomonocytic Leukemia
17. Januar 2017 07:30 ET | Kura Oncology, Inc.
LA JOLLA, Calif., Jan. 17, 2017 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq:KURA), a clinical stage biopharmaceutical company, today announced that the first patient has been dosed in its Phase...
Kura Oncology Logo
Kura Oncology Initiates Phase 2 Study of Tipifarnib in Peripheral T-cell Lymphoma
30. September 2015 07:30 ET | Kura Oncology, Inc.
LA JOLLA, Calif., Sept. 30, 2015 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (OTCQB:KURO), a clinical stage biopharmaceutical company advancing a pipeline of precision medicines for the treatment of solid...